2022 World Conference on Lung Cancer (ePosters)-EP08.01-083. Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden

EP08.01-083. Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden

Back to course

Pdf Summary

This study examined the PD-L1 testing rates, first-line treatment patterns, and real-world outcomes for patients with advanced non-small cell lung cancer (NSCLC) in Sweden since the introduction of immunotherapy. The majority of patients diagnosed with advanced NSCLC were tested for PD-L1 expression, in line with clinical guidelines. However, platinum-based chemotherapy remained a commonly used initial treatment option, although there was a decreasing trend over time. Real-world overall survival (OS) estimates for patients receiving PD-(L)1 inhibitor-based regimens were similar to findings from clinical trials and were longer than OS for patients receiving platinum-based chemotherapy. Among patients initiating PD-(L)1 inhibitor monotherapy for nonsquamous advanced NSCLC, the median OS was 18.6 months, while for squamous advanced NSCLC, it was 13.3 months. For patients with nonsquamous NSCLC receiving PD-(L)1 inhibitor combination therapy, the median OS was 24.0 months, but only a small number of patients with squamous NSCLC received this treatment. Patients receiving platinum-based chemotherapy combination regimens had a median OS of 9.5 months for nonsquamous NSCLC and 11.7 months for squamous NSCLC. These findings provide insights into the current treatment landscape in Sweden for advanced NSCLC and suggest that PD-(L)1 inhibitor therapies may offer improved survival outcomes compared to platinum-based chemotherapy.

Asset Subtitle

Simon Ekman

Meta Tag

Speaker Simon Ekman

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

PD-L1 testing rates

first-line treatment patterns

real-world outcomes

advanced non-small cell lung cancer

NSCLC

Sweden

immunotherapy

platinum-based chemotherapy

PD-(L)1 inhibitor-based regimens

overall survival estimates